-
Mashup Score: 13Colchicine fails to reduce primary outcomes in COP-AF trial but encouraging signals found - 8 month(s) ago
Your access to the latest cardiovascular news, science, tools and resources.
Source: www.escardio.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
We found 2 genomic regions associated with gastrointestinal events in patients treated with colchicine. Those findings will benefit from replication to confirm that some patients may have genetic predispositions to lower tolerability of treatment with colchicine.
Source: pubmed.ncbi.nlm.nih.govCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 4P2Y12 Inhibitor Monotherapy Combined With Colchicine Following PCI in ACS Patients: The MACT Pilot Study - 9 month(s) ago
Abstract Background After a brief period of dual antiplatelet therapy, P2Y12 inhibitor monotherapy in the absence of aspirin effectively reduces bleeding without increasing recurrent ischemia in pa…
Source: www.jacc.orgCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 18
Colchicine and prednisone exhibit equivalent short-term efficacy for the treatment of acute calcium pyrophosphate crystal arthritis, with different safety profiles in the older population.
Source: www.thelancet.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 6Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease: JACC Review Topic of the Week - 9 month(s) ago
Abstract Among statin-treated patients, inflammation assessed by means of high-sensitivity C-reactive protein (hsCRP) is a more powerful determinant of cardiovascular death and all-cause mortality …
Source: www.jacc.orgCategories: Cardiologists1, Latest HeadlinesTweet
-
Mashup Score: 93
The US Food and Drug Administration (FDA) has recently approved colchicine to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization,
Source: academic.oup.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 12
The US Food and Drug Administration (FDA) has recently approved colchicine to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization,
Source: academic.oup.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1Modulation and personalization of therapy after acute coronary syndromes: the road to precision - 9 month(s) ago
The mortality and morbidity associated with acute coronary syndromes (ACSs) have declined markedly over the past 50 years, mainly due to the introduction of the
Source: academic.oup.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0First anti-inflammatory medication approved for treatment of ASCVD - 10 month(s) ago
Low-dose colchicine, an anti-inflammatory drug, was recently approved by the FDA to reduce risk of cardiovascular events
Source: peterattiamd.comCategories: Cardiologists1, Latest HeadlinesTweet
-
Mashup Score: 0What will Lodoco cost? Looking ahead after FDA’s historic approval of colchicine for CVD - 10 month(s) ago
“Our pricing strategy for Lodoco is focused on helping to ensure access to as many people as possible,” an executive with Agepha Pharma told Cardiovascular Business.
Source: Cardiovascular BusinessCategories: Cardiology News and Journals, Latest HeadlinesTweet
#Colchicine fails to reduce primary outcomes in COP-AF trial but encouraging signals found https://t.co/UFpAZ546iX #ESCCongress #Afib https://t.co/xrZRYWP2LH